© Springer International Publishing AG 2018 185
A.S. Cheifetz, J.D. Feuerstein (eds.), Treatment of Inflammatory
Bowel Disease with Biologics, https://doi.org/10.1007/978-3-319-60276-9_12
Chapter 12
Infectious Complications of Biologics
Renée M. Marchioni Beery and Joshua R. Korzenik
Abbreviations
CDI Clostridium difficile infection
CI Confidence interval
CMV Cytomegalovirus
DNA Deoxyribonucleic acid
EBV Epstein-Barr virus
FDA Food and Drug Administration
HBc Hepatitis B core
HBsAb Hepatitis B surface antibody
HBsAg Hepatitis B surface antigen
HBV Hepatitis B virus
HCV Hepatitis C virus
HR Hazard ratio
HSV Herpes simplex virus
IBD Inflammatory bowel disease
JC John Cunningham
OR Odds ratio
PCP Pneumocystis pneumonia
PML Progressive multifocal leukoencephalopathy
PYF Patient-years of follow-up
R.M. Marchioni Beery (*) • J.R. Korzenik
Division of Gastroenterology, Hepatology, and Endoscopy, Brigham and Women’s Hospital,
Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA
e-mail: [email protected]; [email protected]